Abstract 3350
Background
Clinical pathways in oncology have become increasingly complex, involving several different healthcare professionals inside and outside the hospital setting who need particular coordination to provide appropriate care for patients. Very few QI exist to evaluate the oncological clinical pathway in its entirety, particularly regarding the various stages between patient admissions and discharges and the liaisons with non-hospital healthcare professionals (e.g. GPs, pharmacists). Our objective is to select a number of QI describing the oncological clinical pathway with an expert panel.
Methods
A systematic review of available QI describing the oncological clinical pathways in the literature was conducted. The list of selected QI was presented to an expert panel (oncologists, pharmacists and SRNs) of various hospitals in France. The selection involved a two-step process: a preliminary selection was conducted based on the title and rationale of the QI by consensus (nominal group), assigning a value to each QI reviewed on the basis of its appropriateness and its feasibility (1st working group). The pre-selected QI were then described in detail and presented to the expert panel (2nd working group) in order to validate the selection.
Results
5731 QI were identified in the literature review and 131 included. 17 indicators were pre-selected by the experts (1st working group). After presentation of the 17 detailed descriptors, the QIs were clustered or eliminated. Ultimately, 10 QI were selected (Table): outcome (2), process (3) and structure (5).Table: 1658P
QI | Description | Type |
---|---|---|
1 | Symptoms and disease progression | Structure |
2 | Assessment of tolerance to treatment | Process |
3 | Management of patients receiving oral therapy | Structure |
4 | Quality of the liaison document | Process |
5 | Composite score for supportive care | Structure |
6 | Patient therapeutic education | Structure |
7 | Medication reconciliation | Process |
8 | Unscheduled admissions | Outcome |
9 | Declaration and follow-up upon serious adverse events in clinical pathway | Structure |
10 | Patient’s experience (PREMS) | Outcome |
Conclusions
This approach will be developed further by presenting the IQs to patient associations and primary care physicians in order to gather their feedback, refine, adapt and ultimately create a representative set of indicators.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Novartis Oncology France.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5031 - Sarcoidosis-Like Reaction Mimics Progression in patients treated with immune checkpoint inhibitors
Presenter: Sophie Hans
Session: Poster Display session 3
Resources:
Abstract
5650 - Tissue-based activation of mucosal-associated invariant T (MAIT) cells in combination ipilimumab and nivolumab checkpoint inhibitor (CI) colitis.
Presenter: Sarah Sasson
Session: Poster Display session 3
Resources:
Abstract
5944 - Significance of severe immune-related adverse effects (irAE) on patients with advanced tumors treated with immune checkpoint inhibitors being admitted for secondary toxicity: Clinical relevance and next steps
Presenter: Leyre Zubiri
Session: Poster Display session 3
Resources:
Abstract
5989 - Implementation of a dedicated immuno-oncology toxicity service reduces the acute impact of immune-related adverse events
Presenter: Anna Olsson-Brown
Session: Poster Display session 3
Resources:
Abstract
3267 - Cardiotoxic and pro-inflammatory effects induced by the association of immune checkpoint inhibitor Pembrolizumab and Trastuzumab in preclinical models
Presenter: Nicola Maurea
Session: Poster Display session 3
Resources:
Abstract
3417 - Interstitial lung disease associated with immune-checkpoint inhibitors in malignant diseases
Presenter: Akira Yamagata
Session: Poster Display session 3
Resources:
Abstract
2071 - A Phase 1 Study of Intraperitoneal MCY-M11 Anti-Mesothelin CAR for Women with Platinum Resistant High Grade Serous Adenocarcinoma of the Ovary, Primary Peritoneum, or Fallopian Tube, or Subjects with Peritoneal Mesothelioma with Recurrence after Prior Chemotherapy
Presenter: Christina Annunziata
Session: Poster Display session 3
Resources:
Abstract
4935 - Trial in progress: First-in-human study of a novel anti-NY-ESO-1–anti-CD3, TCR-based bispecific (IMCnyeso) as monotherapy in NY-ESO-1/LAGE-1A-positive advanced solid tumors (IMCnyeso-101)
Presenter: Juanita Lopez
Session: Poster Display session 3
Resources:
Abstract
5613 - Nimotuzumab-Cisplatin-Radiation versus Cisplatin-Radiation in HPV negative oropharyngeal cancer
Presenter: Kumar Prabhash
Session: Poster Display session 3
Resources:
Abstract
2576 - Interim analysis of a single arm phase 2 study of adjuvant nivolumab after salvage resection in head and neck squamous cell carcinoma patients previously treated with definitive therapy.
Presenter: Trisha Wise-draper
Session: Poster Display session 3
Resources:
Abstract